{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:06:05Z","timestamp":1789729565156,"version":"4.0.1"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-derived prostate cancer organoids (PCOs) represent a promising 3D model that largely preserves the genomic, phenotypic, and functional signatures of primary tumors. Building on prior studies that mostly focus on fragmented analyses and lack in-depth systematic integration, this narrative review attempts to establish a refined multidimensional research framework centered on \u201cmodel optimization-mechanism exploration-clinical translation\u201d. Notably, it underscores the unique advantages of engineered PCOs and heterotypic co-culture organoid systems in resolving key clinical bottlenecks, particularly lineage transformation-driven therapeutic resistance and patient-specific TME heterogeneity. This study systematically elaborates the establishment methodologies of PCOs, critically evaluates the strengths, limitations, and iterative optimization strategies of diverse culture systems, and summarizes the core applications of PCOs in exploring tumor cellular origin, capturing tumor heterogeneity, modeling TME interactions, screening drug sensitivity, investigating resistance mechanisms, and advancing precision medicine for prostate cancer. Although PCO-based platforms still possess inherent limitations, including low establishment efficiency, rigorous culture requirements, and incomplete TME reconstruction, they harbor substantial translational potential. Furthermore, this review proposes targeted optimization strategies based on bioengineering and synthetic biomaterials, prospects the clinical translation of standardized PCO systems, and discusses existing research contradictions and unaddressed gaps in this field, aiming to provide a comprehensive, critical and novel theoretical reference for further basic research and clinical application of PCOs in prostate cancer.<\/jats:p>","DOI":"10.3389\/fonc.2026.1939330","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:40:52Z","timestamp":1789728052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingzhen","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Changzhou Hospital of Traditional Chinese Medicine, Changzhou Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Changzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kingbio Medical Co., Ltd.","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihai","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of Huzhou Normal University","place":["Huzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/jci128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine differentiation in prostate cancer: Emerging biology, models, and therapies","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2293757","article-title":"Novel signatures of prostate cancer progression and therapeutic resistance","volume":"27","author":"Wang","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010074","article-title":"Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells","volume":"8","author":"Namekawa","year":"2019","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-13-2971","article-title":"Cancer cell lines for drug discovery and development","volume":"74","author":"Wilding","year":"2014","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.cd-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14441","article-title":"Current experimental human tissue-derived models for prostate cancer research","volume":"28","author":"Kato","year":"2021","journal-title":"Int J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12224","article-title":"Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy","volume":"41","author":"Qu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0409","article-title":"A PDX\/Organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ydbio.2007.09.042","article-title":"Anchorage-independent culture maintains prostate stem cells","volume":"312","author":"Shi","year":"2007","journal-title":"Dev Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat Protoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2010.11","article-title":"Isolation, cultivation and characterization of adult murine prostate stem cells","volume":"5","author":"Lukacs","year":"2010","journal-title":"Nat Protoc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.017","article-title":"Identification of multipotent luminal progenitor cells in human prostate organoid cultures","volume":"159","author":"Karthaus","year":"2014","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1603645113","article-title":"Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay","volume":"113","author":"Park","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx165","article-title":"CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/ol.2021.13124","article-title":"Establishment and characterization of prostate organoids from treatment-na\u00efve patients with prostate cancer","volume":"23","author":"Cheaito","year":"2022","journal-title":"Oncol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13382","article-title":"Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease","volume":"17","author":"Elsesy","year":"2023","journal-title":"Mol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1011652","article-title":"Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment","volume":"21","author":"Lee","year":"2025","journal-title":"PloS Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100096","article-title":"Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors","volume":"34","author":"Mosquera","year":"2022","journal-title":"Adv Mater"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","article-title":"Spherical cancer models in tumor biology","volume":"17","author":"Weiswald","year":"2015","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202200434","article-title":"Microwell-based flow culture increases viability and restores drug response in prostate cancer spheroids","volume":"18","author":"Payne","year":"2023","journal-title":"Biotechnol J"},{"key":"B33","article-title":"Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341","volume":"6","author":"Frankel","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111029","article-title":"3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer","volume":"9","author":"Chambers","year":"2014","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41598-017-18050-1","article-title":"The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform","volume":"8","author":"Mosaad","year":"2018","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00166","article-title":"Modeling cell communication in cancer with organoids: Making the complex simple","volume":"8","author":"Fiorini","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-4429","article-title":"Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and Malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens","volume":"67","author":"Miki","year":"2007","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3047","article-title":"Single luminal epithelial progenitors can generate prostate organoids in culture","volume":"16","author":"Chua","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010431","article-title":"A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses","volume":"5","author":"H\u00e4rm\u00e4","year":"2010","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"254ra125","DOI":"10.1126\/scitranslmed.3009448","article-title":"Tumor clone dynamics in lethal prostate cancer","volume":"6","author":"Carreira","year":"2014","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","volume":"649","author":"Li","year":"2026","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"116950","DOI":"10.1016\/j.celrep.2026.116950","article-title":"FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity","volume":"45","author":"Ladewig","year":"2026","journal-title":"Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101758","article-title":"CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13","volume":"5","author":"Tien","year":"2024","journal-title":"Cell Rep Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-0636","article-title":"Epigenetic derepression of PROX1 promotes neuroendocrine prostate cancer progression","volume":"85","author":"Venkadakrishnan","year":"2025","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17305\/bjbms.2015.449","article-title":"Prostate cancer stroma: an important factor in cancer growth and progression","volume":"15","author":"Kru\u0161lin","year":"2015","journal-title":"Bosn J Basic Med Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.10.059","article-title":"A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions","volume":"77","author":"Fong","year":"2016","journal-title":"Biomaterials"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091458","article-title":"Cancer-associated fibroblasts modify the response of prostate cancer cells to androgen and anti-androgens in three-dimensional spheroid culture","volume":"17","author":"Eder","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0505-5","article-title":"Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis","volume":"18","author":"Neuwirt","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.01.028","article-title":"Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids","volume":"12","author":"Richards","year":"2019","journal-title":"iScience"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70240","article-title":"Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models","volume":"13","author":"Afshan","year":"2024","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28971","article-title":"Bioengineered tumor-stroma prostate cancer in vitro models for screening therapeutics","volume":"122","author":"Monteiro","year":"2025","journal-title":"Biotechnol Bioeng"},{"key":"B53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bit.28971","article-title":"Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers","volume":"56","author":"Seo","year":"2023","journal-title":"BMB Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01012","article-title":"Dual-mTOR inhibitor Rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity","volume":"10","author":"La Manna","year":"2020","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade8641","article-title":"PI5P4K\u03b1 supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition","volume":"9","author":"Triscott","year":"2023","journal-title":"Sci Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736431","article-title":"Application of organoid models in prostate cancer research","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17239","DOI":"10.1038\/s41598-018-35417-0","article-title":"High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer","volume":"8","author":"Jansson","year":"2018","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2602324","article-title":"Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening","volume":"57","author":"Qian","year":"2025","journal-title":"Ann Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","first-page":"955","DOI":"10.15252\/msb.20177697","article-title":"Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations","volume":"13","author":"Jabs","year":"2017","journal-title":"Mol Syst Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"10.3791\/60346","DOI":"10.3791\/60346","article-title":"Prostate organoid cultures as tools to translate genotypes and mutational profiles to pharmacological responses","volume":"152","author":"Pappas","year":"2019","journal-title":"J Vis Exp"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910659","article-title":"The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer","volume":"11","author":"Yan","year":"2019","journal-title":"EMBO Mol Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114098","article-title":"Targeting cancer drug resistance utilizing organoid technology","volume":"158","author":"Chai","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063203","article-title":"Novel dormancy mechanism of castration resistance in bone metastatic prostate cancer organoids","volume":"23","author":"Lee","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.ccr-18-1912","article-title":"A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243973","article-title":"A patient-derived organoid platform from TUR-P samples enables precision drug screening in advanced prostate cancer","volume":"17","author":"Ali","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","article-title":"Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer","volume":"38","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/path.5698","article-title":"Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens","volume":"254","author":"Servant","year":"2021","journal-title":"J Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/jci169616","article-title":"Prostate organoids: emerging experimental tools for translational research","volume":"133","author":"Beshiri","year":"2023","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1139\/o86-084","article-title":"Stromal-epithelial interactions and heterogeneity of proliferative activity within the prostate","volume":"64","author":"Cunha","year":"1986","journal-title":"Biochem Cell Biol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033688","article-title":"Metastases in prostate cancer","volume":"9","author":"Manna","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003213","article-title":"Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids","volume":"9","author":"Meng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10544-025-00773-y","article-title":"Engineering vascularized brain tumor organoids: bridging the gap between models and reality","volume":"27","author":"Hariri","year":"2025","journal-title":"BioMed Microdevices"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1400","article-title":"Modelling the tumor immune microenvironment for precision immunotherapy","volume":"11","author":"Mackenzie","year":"2022","journal-title":"Clin Transl Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:40:53Z","timestamp":1789728053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":82,"alternative-id":["10.3389\/fonc.2026.1939330"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1939330","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1939330"}}